IRES-puro-GFP Citations (4)

Originally described in: Use of isogenic human cancer cells for high-throughput screening and drug discovery.
Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW Nat Biotechnol. 2001 Oct . 19(10):940-5. PubMed Journal

---

Articles Citing IRES-puro-GFP

Articles
Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis. Chakraborty S, Ji H, Chen J, Gersbach CA, Leong KW. Sci Rep. 2014 Dec 10;4:7403. doi: 10.1038/srep07403. PubMed
Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Shinkuma S, Guo Z, Christiano AM. Proc Natl Acad Sci U S A. 2016 May 17;113(20):5676-81. doi: 10.1073/pnas.1512028113. Epub 2016 May 3. PubMed
Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Palstra RJ, de Crignis E, Roling MD, van Staveren T, Kan TW, van Ijcken W, Mueller YM, Katsikis PD, Mahmoudi T. Sci Adv. 2018 Feb 21;4(2):e1701729. doi: 10.1126/sciadv.1701729. eCollection 2018 Feb. PubMed
Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR/Cas9. Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, Iwata H, Nakamura H, Vorobyev A, Abe R, Shimizu H. J Invest Dermatol. 2019 Aug;139(8):1711-1721.e4. doi: 10.1016/j.jid.2019.02.015. Epub 2019 Mar 1. PubMed

If you have published an article using this material, please email us at to have your article added to this page.